Related Experiment Video
Updated: May 28, 2026
05:39
Acupoint Needle-Embedding Combined with Ironing Therapy for Postoperative Pain After Anal Surgery
Published on: June 23, 2023
Colonic butyrate- algesic or analgesic?
P Kannampalli1, R Shaker, J N Sengupta
1Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI 53226, USA. sengupta@mcw.edu
Neurogastroenterology and Motility
|October 11, 2011
Summary
Butyrate, produced from dietary fiber, has conflicting effects on visceral hypersensitivity in irritable bowel syndrome (IBS). Understanding its molecular mechanisms is crucial before recommending fiber-rich diets for IBS patients.
Area of Science:
- Gastroenterology
- Molecular Biology
- Nutritional Science
Background:
- Irritable bowel syndrome (IBS) presents complex symptoms like abdominal pain and altered bowel movements, challenging treatment.
- Current IBS therapies aim to alleviate abdominal pain and improve patient quality of life.
- Dietary fiber is often recommended for IBS, but its efficacy, particularly regarding butyrate production, is debated.
Purpose of the Study:
- To investigate the contrasting effects of intra-colonic butyrate on visceral hypersensitivity.
- To elucidate the molecular mechanisms underlying butyrate's differential impact in rats and humans.
Main Methods:
- Review of existing literature on butyrate's role in visceral sensitivity.
- Analysis of studies reporting butyrate's effects in animal models (rats) and human subjects.
Main Results:
- In rats, butyrate has been shown to induce visceral hypersensitivity without observable pathology.
- In human studies, butyrate has been reported to reduce visceral pain.
Conclusions:
- Conflicting evidence exists regarding butyrate's function in visceral pain perception.
- Further research into the molecular mechanisms of butyrate is essential for informed dietary recommendations in IBS management.
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...